Developing a robust go-to-market strategy requires understanding what healthcare providers are treating your target patient population and how those patients are being cared for today. Health insurance claims are submitted for every service and procedure delivered by doctors or hospitals who seek reimbursement. The claim contains a rich trove of data about the patient, the diagnoses made, the procedures performed and the providers involved in that care.
Definitive, Truven, DRG, IMS (IQVIA), Blue Health, Symphony and others all sell some combination of healthcare claims from clearinghouses (private payer claims) or the government (Medicare claims). Some have more coverage, some less but you should anticipate spending $200k+ for a national cross-payer dataset in one therapeutic area. Before you write a check for a big purchase of claims-based datasets, consider other sources of this valuable information that doesn’t blow your budget.
Katie Vahle, Chief Commercial Officer at Carevoyance, will make a case for using claims data to inform your commercialization development strategy. We’ll review the high level reimbursement process to understand what data is available. You will leave the discussion with a framework for how to access and leverage this type of healthcare data in your go-to-market strategies – whether you are developing your first go-to-market strategy, considering expanding into new markets / indications, or simply trying to gain better insights into your customer and prospect base.
About the Speaker
Katie Vahle is the Chief Commercial Officer at Carevoyance, a healthcare insights platform. Carevoyance aggregates and analyzes disparate data sources (from both private and public sources) to create a powerful search and reporting resource for MedTech product and commercialization teams. With 20+ years experience in building and selling products for doctors & hospitals, Carevoyance was created to address inefficiencies in targeting and engaging healthcare providers on new medical technologies.